Company intelligence / Profile preview

emp BIOTECH

Ownership: Private
Development stage: Commercial

Overview

emp BIOTECH does not develop drugs but provides high-quality reagents and technologies that support R&D through to large-scale manufacturing in pharma/biotech. Their products are used in the synthesis/purification of oligonucleotides/proteins/antibodies

Therapeutic areas: Other
Modalities: Small moleculeOligonucleotideProtein
Industry: Chemicals & Materials

Partnerships

Exclusive European distributor for ChemGenes dye amidites

Beyond the preview

Go deeper on emp BIOTECH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on emp BIOTECH.

Explore the full profile